Exhibit 99.2
  o Small Claims
    
    o County Court
    
    þ District Courto Probate Court
    
    o Juvenile Court
    
    o Water Court
  Court Address:
    
    100 Jefferson County Parkway
Golden, Colorado 80401
 
    Attorneys for Plaintiffs
 5 COURT USE ONLY 5
   AMENDED CLASS ACTION COMPLAINT




---



##### 



o Small Claims
    
    o County Court
    
    þ District Courto Probate Court
    
    o Juvenile Court
    
    o Water Court
  Court Address:
    
    100 Jefferson County Parkway
Golden, Colorado 80401
 
    Attorneys for Plaintiff and Class
 5 COURT USE ONLY 5
    2




---



##### 



o Small Claims
    
    o County Court
    
    þ District Courto Probate Court
    
    o Juvenile Court
    
    o Water Court
  Court Address:
    
    100 Jefferson County Parkway
Golden, Colorado 80401
 
    Attorneys for Plaintiffs and Class
 5 COURT USE ONLY 5
   3




---



##### 



inter alia
 SUMMARY OF ACTION
    4




---



##### 



5




---



##### 



inter alia,
 6




---



##### 



inter alia
 PARTIES
    7




---



##### 



8




---



##### 



9




---



##### 



INDIVIDUAL DEFENDANTS FIDUCIARY DUTIES
       10




---



##### 



CONSPIRACY, AIDING AND ABETTING AND CONCERTED ACTION
  11




---



##### 



inter alia
 I. CLASS ACTION ALLEGATIONS
   12




---



##### 



inter alia
          13




---



##### 



SUBSTANTIVE ALLEGATIONS
 A. Global Meds Impressive Track Record of Growth
   74% over the $9.438 million recorded for the first half of 2008
 an
increase of $3.214 million or 66% over the $4.845 million recorded for the comparable 2008
period
 14




---



##### 



the verIDhemos system is a green field market
opportunity for Global Med After Global Meds team saw the verIDhemos system used in a clinical
setting, we knew that the product had tremendous potential for worldwide distribution
 exclusive marketing rights in North America, Japan, Brazil,
most of Europe, the Middle East and Asia Global Med will be seeking FDA permission to market the verIDhemos product in
2010. Plans are for immediate marketing of the product in Germany and France With Global
Meds international market reach, we are all very excited about verIDhemos substantial
market potential
 15




---



##### 



The LOI with VerIDentia has provided us with exclusive marketing rights in North America,
Japan, Brazil, most of Europe, the Middle East and Asia. Although it is not currently
available for sale in the U.S., Global Med will be seeking FDA clearance to market the
verIDhemos product in 2010. We believe our relationship with VerIDentia will provide us
with opportunities for additional sales to our existing customer base and elsewhere
  
    
    Net income for the three months ended September 30, 2009 was a record $1.10 million
compared to a net loss of $228,000 for the comparable period in 2008.
    
    Operating income improved to $1.12 million for the third quarter of 2009 from a $118,000
loss during the comparable 2008 period.
    
    For the first nine months of 2009, the Companys revenues increased to $23.68 million or
a 45% increase over the $16.38 million in revenues recognized during the comparable period
in 2008.
    
    The Companys third quarter revenues increased to $7.26 million representing a 5%
increase from the $6.94 million in the comparable period in 2008.
    
    For the nine months ended September 30, 2009, income from operations improved to $2.80
million from $840,000 for the comparable period during 2008.
 16




---



##### 




    
    The Companys net income for the first nine months of 2009 was $1.70 million versus
$284,000 for the comparable period during 2008.
    
    Cash flow from operations for the first nine months of 2009 was $3.87 million, a more
than 248% increase over the $1.11 million recorded for the first nine months of 2008.
  Mick Ruxin, M.D., Chairman and CEO of Global Med Technologies, Inc., commenting on todays
announcement stated, The Company continues to increase revenue and profitsin spite of the
difficult economic climate. Although we continue to experience a longer sales cycle in the
United States, we are pleased that our organic business revenues have continued to grow. In
addition, we have seen a 23% increase in our Companys backlog from the comparable quarter
during 2008. Our Inlog and eDonor acquisitions are providing us with a number of
cross-selling opportunities that have already begun to yield benefits, and we expect that
trend to continue. (Emphasis added).
 B. The Proposed Transaction and the Merger Agreement
  February, 1, 2010, El Dorado Hills, CA and Braintree, MA, USA and Limonest, France 
Haemonetics Corporation (NYSE: HAE) and Global Med Technologies, Inc. (OTCBB: GLOB) today
announced a definitive agreement under which Haemonetics will acquire Global Med for
approximately $60 million in a cash tender offer.
  Under the terms of the agreement, Haemonetics will commence a tender offer to purchase all
outstanding shares of Global Meds common stock at $1.22 per share and preferred stock at
approximately $1,694 per share. The tender offer is conditioned on the tender of a majority
of the outstanding shares of Global Meds common and preferred stock, and subject to other
customary closing conditions. The $60 million estimated net value of the transaction is
based on Global Meds 49 million diluted common equivalent shares outstanding. Haemonetics
will fund
 17




---



##### 



the acquisition from available cash and anticipates that it will continue to have more
than $100 million in cash on the balance sheet at fiscal year end.
  The scale of the combined entities will create a $60 million software organization with
greater resources for product development, an expanded knowledge-base in IT, and more
extensive global reach. Combined, we expect to be an even stronger partner with our
customers in delivering best blood management practices.The demand for information technology platforms across the blood management supply chain
is approximately $580 million.(Emphasis added).
 fait
daccompli
   18




---



##### 



fait
accompli
   19




---



##### 



C. Inadequate Disclosures in Global Meds Schedule 14D-9
   (i)
    
    The Schedule 14D-9 provides insufficient information about Global Meds
projections, insofar provides only projections for 2009 to 2010.
Accordingly, a complete set of financial projections (including Free Cash
Flows for 2009-2014) of the Company for years 2009 through 2014 relied
upon by St. Charles in rendering its fairness opinion should be disclosed.(ii)
    
    Fails to disclose the criteria utilized by St. Charles to select the companies
used and/or complete list of multiples observed in its Comparable Public companies
Analysis.(iii)
    
    Fails to disclose the criteria utilized by St. Charles to select the
transactions used in its Comparable Transaction Analysisand the announcement date
for each transaction. In particular, the Schedule 14D-9 indicates the transactions
date back to January 1, 2007 but the multiples have a footnote indicating that the
they reflect LTM as of September 30, 2009 which is hard to reconcile since some of
these transactions might have been consummated pre-Sept 30, 2008 (i.e., Cegedim
SA). Therefore,
 20




---



##### 



additional language is necessary for clarification purposes and to avoid
misleading statements.(iv)
    
    Fails to disclose the conclusions drawn by St. Charles from the
Comparable Public companies Analysis, and Comparable Transaction Analysis.
(i.e. whether and how the implied per share equity range calculated from
those analyses factored in to the determination that the Proposed
Transaction was fair.)(v)
    
    Fails to disclose the criteria utilized by St. Charles in selecting terminal
multiples of EBITDA ranging from 12.5x to 16.5x and discount rates ranging from of
10.0% to 18.0% in its Discounted Cash Flow Analysis.This information is germane to
the analysis especially in light of the wide ranges selected. In addition a
definition of free cash flows utilized by St. Charles in the Discounted Cash Flow
Analysismust be disclosed.
   21




---



##### 



D. Unfair Price
    22




---



##### 



CLAIMS FOR RELIEF
 COUNT I
Breach of Fiduciary Duty  Failure to Maximize Shareholder Value
(Against All Individual Defendants)
    23




---



##### 



COUNT II
Breach of Fiduciary Duty  Disclosure
(Against Individual Defendants)
       COUNT III
Aiding and Abetting
(Against Global Med and Haemonetics)
   24




---



##### 



WHEREFORE
       25




---



##### 



Dated: March 9, 2010
    
    THE SHUMAN LAW FIRM/s/ Kip B. Shuman

Kip B. Shuman

Rusty E. Glenn885 Arapahoe AvenueBoulder, CO 80302(303) 861-3003(303) 484-4886 (fax)Proposed Liaison CounselLEVI & KORSINSKY, LLPJoseph LeviJuan E. Monteverde30 Broad Street, 15th FloorNew York, NY 10006Tel: (212) 363-7500Fax: (212) 363-7171HARWOOD FEFFER, LLPRobert HarwoodJames G. Flynn488 Madison Avenue, 8th FloorNew York, NY 10022(212) 935-7400(212) 753-3630 (fax)BULL & LIFSHITZ, LLPJoshua M. LifshitzPeter Bull18 East 41st Street, 11th FloorNew York, New York 10017(212) 213-6222(212) 213-9405 (fax)Proposed Co-Lead Counsel
 26




---



##### 



Certificate of Service
  K&L Gates LLP
 Attorney for Defendants Global Med Technologies, Inc., Michael Ruxin and Thomas Marcinek
 Katten Muchin Rosenman LLP
 Attorney for Defendants Sarah Eames, Robert Gilmore, and T. Kendall Hunt
 Goodwin Procter
 Attorney for Defendants Haemonetics Corporation and Atlas Acquisition Corp.
 Moye White
 
 Attorney for Defendant Haemonetics Corporation
 [Duly signed original on file]Rusty E. Glenn 27